BofA analyst Tazeen Ahmad raised the firm’s price target on Apellis (APLS) to $28 from $27 and keeps a Neutral rating on the shares following the Q4 pre-announcement made in conjunction with the JPMorgan healthcare conference.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $35 from $39 at Cantor Fitzgerald
- Apellis Pharmaceuticals: Syfovre and Empaveli Outperformance Plus Pipeline Upside Support Undervalued Buy Rating and $45 Target
- Apellis Pharmaceuticals: Durable Growth Outlook and Multiple 2025–2026 Catalysts Support Buy Rating
- Apellis Pharmaceuticals: Empaveli Momentum, Syfovre Franchise Durability, and Multi-Indication Expansion Support Reiterated Buy and $45 Target
- Apellis falls -17.3%